What are analysts'target prices for Arena Pharmaceuticals (Arna) stock?
12 Wall Street analysts have issued 12-month target prices for Arena Pharmaceuticals' shares. Their forecasts range from $71.00 to $120.00. On average, they expect Arena Pharmaceuticals' stock price to reach $96.67 in the next twelve months.
Where can I buy shares of Arna?
Shares of ARNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here.
Which stocks have the highest asset turnover ratios for Arna?
MRSN, CRBP, and ARWR are the stocks whose asset turnover ratios are most correlated with ARNA. The table below shows ARNA's key quality metrics over time. For more insight on analysts targets of ARNA, see our ARNA price target page.
Is Arena Pharmaceuticals stock a good dividend growth stock to buy?
Arena Pharmaceuticals does not have a long track record of dividend growth. In the past three months, Arena Pharmaceuticals insiders have not sold or bought any company stock. Only 3.05% of the stock of Arena Pharmaceuticals is held by insiders. 91.22% of the stock of Arena Pharmaceuticals is held by institutions.
Should I buy ARNA stock?
The consensus among Wall Street research analysts is that investors should "hold" Arena Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ARNA, but not buy additional shares or sell existing shares.
Why did ARNA stock go up?
Covid vaccine maker Pfizer (PFE) said Monday it plans to acquire Arena Pharmaceuticals (ARNA) for $100 a share, in a deal worth an estimated $6.7 billion. The news sent Arena stock rocketing and gave a boost to Pfizer stock.
What happened to Arena Pharmaceuticals stock?
Pfizer has completed its acquisition of all outstanding shares, options, and restricted stock units of Arena for $100 per share, in cash, for a total equity value of approximately $6.7 billion.
What does Arena Pharmaceuticals make?
Arena Pharmaceuticals, Inc. is an American biopharmaceutical company founded in 1997 and headquartered in San Diego, California. The company has small molecule drugs in development for possible clinical utility in multiple therapeutic areas.
How do I buy Pfizer stock?
Open a brokerage account and place your stock order If you don't already have a brokerage account, you'll need one to buy Pfizer or any other stock. You should look for an online broker that charges no commissions on stock trades, and offers a wide investment selection, low or no fees and good customer service.
What company is Pfizer buying?
(NYSE: BHVN) today announced that the companies have entered into a definitive agreement under which Pfizer will acquire Biohaven, the maker of NURTEC® ODT, an innovative dual-acting migraine therapy approved for both acute treatment and episodic prevention of migraine in adults.
Did Pfizer buy Arena Pharmaceuticals?
Pfizer has concluded the takeover of the complete outstanding shares, options and restricted stock units of clinical-stage firm Arena Pharmaceuticals for an equity price of nearly $6.7bn or $100 for each share in cash. In December last year, Pfizer entered a definitive agreement to acquire Arena.
Did Pfizer buy a cardiovascular company?
Pfizer has completed its $6.7 billion acquisition of Arena Pharmaceuticals, finalizing a deal that involves multiple cardiovascular properties. The transaction was first announced back in December 2021.
Component Grades
ARNA POWR Grades
We have 9 different ratings for every stock to help you appreciate its future potential. You can unlock it all now.
ARNA Stock Summary
ARNA scores best on the Growth dimension, with a Growth rank ahead of 23.15% of US stocks.
ARNA's Quality Factors
Arena Pharmaceuticals Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than only 5.55% of US listed stocks.
Latest ARNA News From Around the Web
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
Continue Researching ARNA
Below are the latest news stories about Arena Pharmaceuticals Inc that investors may wish to consider to help them evaluate ARNA as an investment opportunity.
About Arena Pharmaceuticals
Want to see what other sources are saying about Arena Pharmaceuticals Inc's financials and stock price? Try the links below:
Headlines
Arena Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel drugs that target G protien-coupled receptors. It offers drugs for treatment in the field of cardiovascular, central nervous system, inflammatory, and metabolic diseases. The company was founded by Dominic P.
Arena Pharmaceuticals (NASDAQ:ARNA) Frequently Asked Questions
Did The Smart Money Play Arena Pharmaceuticals, Inc. (ARNA) Correctly?
Arena Pharmaceuticals (ARNA)
12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arena Pharmaceuticals in the last twelve months. There are currently 10 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Arena Pharmaceuticals stock.
Arena Pharmaceuticals, Inc. - Hold
This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
Style Scorecard
Zacks' proprietary data indicates that Arena Pharmaceuticals, Inc. is currently rated as a Zacks Rank 3 and we are expecting an inline return from the ARNA shares relative to the market in the next few months. In addition, Arena Pharmaceuticals, Inc.
Chart for ARNA
The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.
What do These Ratings Mean?
San Diego, CA-based Arena Pharmaceuticals is a development-stage biopharmaceutical company focused on developing novel, small molecule drugs as treatment across several therapeutic areas. The company has multiple pipeline candidates in mid/late-stage clinical studies.
What's Happening With Arena Pharmaceuticals, Inc. Stock Today?
Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry.
What do These Ratings Mean?
Arena Pharmaceuticals, Inc. (ARNA) stock is trading at $63.90 as of 11:39 AM on Friday, May 7, an increase of $0.83, or 1.31% from the previous closing price of $63.07. The stock has traded between $62.76 and $66.00 so far today. Volume today is below average. So far 156,867 shares have traded compared to average volume of 480,809 shares.
What's Happening With Arena Pharmaceuticals, Inc. Stock Today?
Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. *Investors Observer* makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.
